A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
2,440estimated
Sites
13
Countries
Honduras, Mexico, Panama
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-11 | actual | When the study began enrolling |
| Primary completion | 2026-08-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-04 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Yellow Fever Immunization
Interventions
- Biological: Yellow fever vaccine (live) — also filed as vYF vaccine
- Biological: Yellow fever vaccine (live) — also filed as Stamaril vaccine
- Biological: Yellow fever vaccine (live) — also filed as YF-VAX vaccine
- Biological: Measles, combinations with mumps and rubella, live attenuated — also filed as MMR II vaccine
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants with seroconversion to YF virus after 1 dose of vYF compared to seroconversion after 1 dose of the Stamaril in YF-naive participants (9-24 months)
measured At Day 29, 28 days post-vaccination (on Day 01) with vYF or Stamaril
Percentage of participants with seroconversion to YF virus after 1 dose of vYF compared to seroconversion after 1 dose of the YF-VAX in YF-naive participants (9-24 months)
measured At Day 29, 28 days post-vaccination (on Day 01) with vYF or YF-VAX
Percentage of participants with seroconversion to YF virus after 1 dose of vYF compared to seroconversion after 1 dose of the Stamaril in YF-naive participants (2-5 years)
measured At Day 29, 28 days post-vaccination (on Day 01) with vYF or Stamaril
Percentage of participants with seroconversion to YF virus after 1 dose of vYF compared to seroconversion after 1 dose of the YF-VAX in YF-naive participants (2-5 years)
measured At Day 29, 28 days post-vaccination (on Day 01) with vYF or YF-VAX
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed